Puma Biotech (PBYI) Tops Q4 EPS by 1c, offers outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts PBYI Hot Sheet
Join SI Premium – FREE
Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of $0.31, $0.01 better than the analyst estimate of $0.30. Revenue for the quarter came in at $72.2 million versus the consensus estimate of $73.55 million.
Outlook Q1 2024:
Net Product Revenue: $38 - $40 million.
Royalty Revenue: $2.5 - $3 million
License Revenue:$0 million
For earnings history and earnings-related data on Puma Biotech (PBYI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- Myriad Genetics (MYGN) Tops Q3 EPS by 9c ; Offers Guidance
- Steris (STE) Tops Q3 EPS by 26c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
